PharmAust Management

Management Kriterienprüfungen 1/4

PharmAust's CEO ist Michael Thurn, ernannt in May 2024, hat eine Amtszeit von weniger als ein Jahr. besitzt direkt 0.61% der Aktien des Unternehmens, im Wert von A$528.00K. Die durchschnittliche Betriebszugehörigkeit des Managementteams und des Verwaltungsrats beträgt 2 Jahre bzw. 3.3 Jahre.

Wichtige Informationen

Michael Thurn

Geschäftsführender

n/a

Gesamtvergütung

Prozentsatz des Geschäftsführergehalts	n/a
Amtszeit als Geschäftsführer	less than a year
Eigentum des Geschäftsführers	0.6%
Durchschnittliche Amtszeit des Managements	less than a year
Durchschnittliche Amtszeit der Vorstandsmitglieder	3.3yrs

Jüngste Management Updates

Here's Why PharmAust Limited's (ASX:PAA) CEO Compensation Is The Least Of Shareholders Concerns

Nov 03

Recent updates

Here's Why We're Not Too Worried About PharmAust's (ASX:PAA) Cash Burn Situation

Apr 09

Here's Why We're Not At All Concerned With PharmAust's (ASX:PAA) Cash Burn Situation

Mar 31

Here's Why PharmAust Limited's (ASX:PAA) CEO Compensation Is The Least Of Shareholders Concerns

Nov 03

Is PharmAust (ASX:PAA) In A Good Position To Deliver On Growth Plans?

May 30

This Is The Reason Why We Think PharmAust Limited's (ASX:PAA) CEO Might Be Underpaid

Oct 14

What Does PharmAust's (ASX:PAA) CEO Pay Reveal?

Feb 14

Geschäftsführer

Michael Thurn

less than a year

Amtszeit

Dr. Michael Thurn, Ph D., serves as Managing Director, CEO and Director of PharmAust Limit since May 31, 2024. He was Chief Executive Officer of PharmAust Limited from September 1, 2023 and was its Directo...

Führungsteam

Name	Position	Amtszeit	Vergütung	Eigentümerschaft
Fiona Milner	General Manager of Epichem Pty Ltd	2yrs	AU$212.10k	keine Daten
Michael Thurn	MD, CEO & Director	less than a year	keine Daten	0.61% A$ 492.0k
John Clark	Chief Operating Officer	less than a year	keine Daten	keine Daten
Gary Pitt	Head of Chemistry	no data	keine Daten	keine Daten
James Rixson	Head of Production	no data	keine Daten	keine Daten
Herbert Brinkman	Head of Manufacturing	less than a year	keine Daten	keine Daten
Nicky Wallis	Chief Scientific Officer	less than a year	keine Daten	keine Daten
Stefan Ross	Company Secretary	less than a year	keine Daten	keine Daten

0.4yrs

Durchschnittliche Betriebszugehörigkeit

Erfahrenes Management: Das Managementteam von PAA gilt nicht als erfahren (durchschnittliche Amszeit 0.4 Jahre), was auf ein neues Team schließen lässt.

Vorstandsmitglieder

Name	Position	Amtszeit	Vergütung	Eigentümerschaft
Michael Thurn	MD, CEO & Director	less than a year	keine Daten	0.61% A$ 492.0k
Christian Schirvel	Veterinary Clinical Advisory Board Member	6.7yrs	keine Daten	keine Daten
Angela Frimberger	Veterinary Clinical Advisory Board Chair	6.7yrs	keine Daten	keine Daten
Barbara Kitchell	Veterinary Advisory Board Member	6.5yrs	keine Daten	keine Daten
Marcus Hughes	Director	less than a year	keine Daten	2.91% A$ 2.4m
Sergio Duchini	Non-Executive Chairman	less than a year	keine Daten	keine Daten

3.3yrs

Durchschnittliche Betriebszugehörigkeit

Erfahrener Vorstand: PAADie Vorstandsmitglieder gelten als erfahren (3.2 Jahre durchschnittliche Amtszeit).

PharmAust Management

Management Kriterienprüfungen 1/4

Wichtige Informationen

Jüngste Management Updates

PharmAust Limited, Annual General Meeting, Nov 20, 2023

PharmAust Limited Announces Executive Changes

PharmAust Limited Appoints Roger Aston as Non-Executive Chairman, Effective 1 September 2023

No independent directors

Here's Why PharmAust Limited's (ASX:PAA) CEO Compensation Is The Least Of Shareholders Concerns

PharmAust Limited, Annual General Meeting, Nov 10, 2022

Recent updates

PharmAust Limited has filed a Follow-on Equity Offering.

Here's Why We're Not Too Worried About PharmAust's (ASX:PAA) Cash Burn Situation

New minor risk - Share price stability

PharmAust Limited has completed a Follow-on Equity Offering in the amount of AUD 3.459 million.

PharmAust Limited has announced a Derivatives Offering in the amount of AUD 39.612456 million.

PharmAust Limited, Annual General Meeting, Nov 20, 2023

New major risk - Revenue and earnings growth

Full year 2023 earnings released: AU$0.019 loss per share (vs AU$0.005 loss in FY 2022)

New minor risk - Financial data availability

PharmAust Limited Announces Executive Changes

PharmAust Limited Appoints Roger Aston as Non-Executive Chairman, Effective 1 September 2023

Here's Why We're Not At All Concerned With PharmAust's (ASX:PAA) Cash Burn Situation

First half 2023 earnings released: EPS: AU$0 (vs AU$0.004 loss in 1H 2022)

PharmAust Limited Progresses to Elevated Doses in MND Patients

PharmAust Limited Completes First Cohort of Six Patients in Its Phase 1/2 Clinical Trial of Lead Drug Candidate Monepantel in Motor Neurone Disease/Amyotrophic Lateral Sclerosis

PharmAust Limited Announces MND Trial Completes Enrolment of First Patient Cohort

No independent directors

Here's Why PharmAust Limited's (ASX:PAA) CEO Compensation Is The Least Of Shareholders Concerns

PharmAust Limited, Annual General Meeting, Nov 10, 2022

PharmAust Limited Recruits First Pet Dog with B Cell Lymphoma in US Canine Phase 2 Trial Assessing the Efficacy of Monepantel Treatment

Full year 2022 earnings released: AU$0.005 loss per share (vs AU$0.004 loss in FY 2021)

Pharmaust Updates on Canine Cancer Trials

Is PharmAust (ASX:PAA) In A Good Position To Deliver On Growth Plans?

PharmAust Limited Announces Resignation of Richard Mollard as Chief Scientific Officer

Pharmaust Limited Announces Arrival of Mpl Tablets in Melbourne for Motor Neuron Disease Clinical Trial

PharmAust Limited Expands Lymphoma Canine Trial to the USA

No independent directors

PharmAust Limited Announces Preliminary MPL Anti-Viral Leukaemia Preclinical WEHI Results

Pharmaust Limited Engages Ergomed Clinical Research Ltd to Commence Clinical Trials Testing the Anti-Viral Effects of Monepantel

First half 2022 earnings: Revenues and EPS in line with analyst expectations

PharmAust Limited Provides Update on Manufacture of MPL & Tablets for Clinical Trials

This Is The Reason Why We Think PharmAust Limited's (ASX:PAA) CEO Might Be Underpaid

Full year 2021 earnings released: AU$0.004 loss per share (vs AU$0.005 loss in FY 2020)

Pharmaust Limited Achieves Phase IIB Dog Trial's Interim Clinical Endpoints

PharmAust Receives Ethics Approval for Phase I Trial of Monepantel in Motor Neurone Disease

PharmAust Limited Announces Phase IIb Canine Trial Identifies Therapeutic Window for MPL

PharmAust Ltd Provides an Update on Phase IIb Trial Testing the Effects of Monepantel Upon Pet Owners' Dogs with Treatment Naïve B Cell Lymphoma

What Does PharmAust's (ASX:PAA) CEO Pay Reveal?

PharmAust Limited Announces Monepantel COVID-19 Testing in the Netherlands

PharmAust and Leiden University Medical Centre Provide Update on Monepantel COVID-19 Testing

PharmAust and Olivia Newton-John Cancer Research Institute to Continue MPL Pre-clinical Investigations

PharmAust Ltd to Commence Phase IIb Dog Cancer Trial

PharmAust Limited Provides an Update on Analysis at the Olivia Newton-John Cancer Research Institute Investigating the Mechanism of Action of Monepantel Upon Cancer Cells

Pharmaust Ltd, Entered into A Service Agreement with Leiden University Medical Center (Lumc) in Netherlands for Lumc to Test

Full year earnings released - AU$0.0046 loss per share

Full year earnings released - AU$0.0046 loss per share

Geschäftsführer

Amtszeit

Führungsteam

Durchschnittliche Betriebszugehörigkeit

Vorstandsmitglieder

Durchschnittliche Betriebszugehörigkeit